Kornimate/medical-research-clean huggingface dataset:
vasostat vs. tr band for radial hemostasis

Conditions: Coronary Artery Disease; Peripheral Arterial Disease

Summary: vasostat vs. tr band compression for radial artery hemostasis following transradial catheterization without prior radial artery access

patients will be enrolled if they are scheduled to undergo a coronary or peripheral catheterization procedure involving the placement of a sheath (plastic tube) in the radial artery near the participants wrist. the purpose of this research is to compare two devices which make bleeding stop after the participants procedure is finished and the plastic tube is removed from the radial artery in the wrist. the two devices are called the vasostat and the tr band. both of these devices are called hemostasis devices, which means they stop bleeding (hemostasis). both devices are approved by the food and drug administration (fda) and are used throughout hospitals in the united states. the investigators will compare blood flow to the hand, and survey patients as to how comfortable these devices are, while they are being used to stop bleeding after the catheterization procedure. patients will be randomized to one device or the other as part of the study. the investigators will noninvasively measure the blood flow to the hand by placing a soft plastic probe on the tip of the thumb called a plethysmography probe. this measurement only takes a few seconds and is painless. the investigators will measure before, after application and after removal \& before patients are discharged. thirty days later, patients will return for another measurement and to examine the radial artery with an ultrasound probe. 40 patients will be enrolled. statistical analysis: based on prior studies, the investigators will assume that the vasostat produces a 30% reduction in hand perfusion during normal clinical use. the investigators assume the tr band produces a 70% reduction in hand perfusion during normal clinical use. using a two-sample test of proportions, with a type i error of 5%, a power of 80%, and an anticipated drop-out rate of 10%, the investigators will need to enroll 40 patients (20 patients in each arm of the study) (statmate 2.0, graphpad software, san diego, ca)

Eligibility criteria:
inclusion criteria: • no prior radial access exclusion criteria: * patients receiving concurrent investigational medications * cellulitis overlying radial artery * oral anticoagulation * patients receiving glycoprotein iib/iiia inhibitors * dementia * prisoners * institutionalized individuals * allergy to medical adhesive * radial sheath \> 6 french (id)

Keywords: vasostat tr band transradial access coronary angiography peripheral arterial disease coronary artery disease peripheral angiography stents
a multicenter prospective clinical cohort study on the pathogen spectrum of severe hepatitis (liver failure) complicated with infection

Conditions: Liver Failure

Summary: the goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with severe hepatitis (liver failure). the main questions it aims to answer are: * mapping of infectious agents in patients with severe hepatitis (liver failure) * constructing early warning predictive models to explore how to give an individualized regimen of integrated immune function.

liver failure is a clinical syndrome caused by a large number of necrotic hepatocytes leading to severe liver function damage, with jaundice, coagulation dysfunction and hepatic encephalopathy as the main manifestations, which can be caused by a variety of reasons, and the liver failure caused by hepatitis b virus (hbv) is the first one in our country, which accounts for about 80% of the cases. through the "eleventh five-year plan" to "thirteenth five-year plan" national scientific and technological major special projects, the death rate of patients with early and middle stage of severe hepatitis b has been significantly reduced, but the death rate of patients with advanced stage is still as high as about 60%, especially when liver failure is combined with other complications, such as this study focuses on the impact of secondary infections on the clinical prognosis of severe hepatitis (liver failure), and intends to establish a prospective, multi-center clinical cohort of secondary infections in liver failure, map the infectious pathogens, correlate the basic immune status with the characteristics of the pathogen profile of the secondary infections, and establish a monitoring and early-warning system of secondary infections, so as to explore safe and effective treatment modalities. to further reduce the mortality rate of liver failure.

Eligibility criteria:
inclusion criteria: 1. patients agreed to participate in the study and signed an informed consent form; 2. sex is not limited and age is 18-70 years old; 3. hbsag positive for more than 6 months, or hepatitis e igm positive, or hepatitis e rna positive; 4. progressive deepening of jaundice in a short period of time (serum total bilirubin greater than 10 times the upper limit of normal or rising ≥17.1 umol/l per day); 5. sgnificant bleeding tendency with pta ≤ 40% and exclusion of other non-hepatic factors. exclusion criteria: 1. patients with severe hepatitis caused by other non-hepatophilic viral infections; 2. patients who were considered by the investigator to be unsuitable for participation in the study.

Keywords: severe hepatitis pathogen pedigree of infection cohort study
a phase iia. open-label, multicenter, dose-escalation study to assess the tolerability and pharmacokinetics of zd4054 (zibotentan) given orally once daily in subjects with metastatic prostate cancer

Conditions: Prostatic Neoplasms; Metastases, Neoplasm

Summary: the primary purpose of this study is to determine the safest dose of zd4054 (zibotentan)in men with prostate cancer


Eligibility criteria:
inclusion criteria: * men 18 years \& older * confirmed diagnosis of prostate cancer with bone metastases exclusion criteria: * no more than 2 prior chemotherapy regimens * no radiation, chemotherapy or bisphosphonates in the past 4 weeks

Keywords: prostate cancer metastatic prostate cancer bone metastases
a one year clinical trial assessing the usefulness and safety of inhaled insulin in diabetics with copd

Conditions: Diabetes Mellitus; Chronic Obstructive Pulmonary Disease

Summary: a one year clinical trial assessing the usefulness and safety of inhaled insulin in diabetics with chronic obstructive pulmonary disease.

pfizer announced in october 2007 that it would stop marketing exubera. at that time recruitment for study a2171030 was placed on hold. nektar, the company from which pfizer licensed exubera, announced on april 9, 2008 that it had stopped its search for a new marketing partner. accordingly, there will be no commercial availability of exubera. as a result, study a2171030 was terminated on june 17, 2008. neither safety nor efficacy reasons were the cause of the study termination.

Eligibility criteria:
inclusion criteria: * diabetes mellitus (type 1 or type 2) currently controlled with injected insulin * prior smokers with a fixed airflow obstruction at screening (fev1/fvc \< 70%) and fev1 \< 80% predicted and/or a history of chronic productive cough. exclusion criteria: * poorly controlled, unstable or steroid-dependent copd, insulin pump therapy, active smoking
study of durvalumab given with chemoradiation therapy in patients with unresectable non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this is a phase iii, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based crt (durvalumab + standard of care \[soc\] crt) in patients with locally advanced, unresectable nsclc (stage iii).


Eligibility criteria:
principal inclusion criteria : * subjects with histologically- or cytologically-documented nsclc * locally advanced, unresectable (stage iii) nsclc * world health organisation (who) performance status 0-1 * at least one measurable lesion, not previously irradiated * must have a life expectancy of at least 12 weeks at randomization principal exclusion criteria : * receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, durvalumab and mabs. * prior exposure to immune-mediated therapy, including but not limited to, other anti ctla-4, anti-pd-1, anti-pd-l1, and anti pd l2 antibodies, excluding therapeutic anticancer vaccines. * history of allogeneic organ transplantation * active or prior documented autoimmune or inflammatory disorders * uncontrolled intercurrent illness * history of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency * active infection including tuberculosis, hepatitis b, hepatitis c, or human immunodeficiency virus * mixed small cell and nsclc histology * any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling * known allergy or hypersensitivity to any of the ips or any of the ip excipients. * patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 gy in total (v20) of more than 35% of lung volume.

Keywords: locally advanced, unresectable nsclc, carcinoma, nsclc
multiple dose effects of hydrochlorothiazide and isosorbide mononitrate on glucose homeostasis (mk-0000-117)(completed)

Conditions: Hypertension

Summary: this study will measure and compare changes in insulin production and sensitivity using the hyperglycemic clamp technique in obese patients with impaired glucose tolerance and hypertension treated with placebo, isosorbide mononitrate (ismn) or hydrochlorothiazide (hctz).


Eligibility criteria:
inclusion criteria: * female participants must be post-menopausal * body mass index (bmi) of at least 29 kg/m\^2 * weight has been stable over the past 3 months * has never been treated for hypertension or is diagnosed with hypertension taking up to 2 anti-hypertensive medications * willing to stop hypertension treatment for 14 days prior to randomization and throughout the study * does not have a history of diabetes * in good health with the exception of hypertension * no history of abnormal heart rhythms * part i only: willing to comply with high potassium/low sodium diet for the duration of the study * willing to avoid strenuous physical activity during the study * nonsmoker and/or has not used nicotine for at least 3 months and agrees to refrain from use of tobacco-containing products throughout the study * agrees to refrain from consuming alcohol and caffeine during in-patient periods and to limit consumption at all other times during the study * agrees not to consume grapefruit, grapefruit products, and citrus, apple, and pineapple juices 2 weeks prior to administration of the first dose of study drug exclusion criteria: * history of any illness that may make their participation in the study unsafe or confuse the study results * taking spironolactone or eplerenone * cannot refrain from using any prescription or non-prescription drugs during the study * on a weight loss program and is not in the maintenance phase * started a weight loss drug within 8 weeks of the first study visit * consumes excessive amounts of alcohol or caffeine * has had major surgery, donated or lost 1 unit of blood within 4 weeks of the first study visit * history of multiple and/or severe allergies to drugs or food * is dehydrated
prevalence and outcome of sars-cov-2 infection & covid-19 in transplant recipients: the covitra study

Conditions: Covid19; SARS-CoV Infection; Transplantation Infection

Summary: this project will provide novel data using a large cohort of more than 3000 transplanted patients. risk and protective factors for sars-cov-2 infection and covid-19 disease severity will be identified. the proportion of patients who develop antibodies after infection will be revealed. in this way the presence of these antibodies can be evaluated as a test for prior infection. our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.


Eligibility criteria:
inclusion criteria: * all patients who underwent solid organ or hematopoietic cell transplantation at uz leuven and who give informed consent exclusion criteria: * age under 18 years

Keywords: covid19 sars-cov infection transplantation
evaluation of an introductory videotape intervention to improve cardiac rehabilitation participation

Conditions: Myocardial Infarction; Unstable Angina; Coronary Angioplasty; Coronary Artery Bypass Surgery

Summary: the purpose of this study is to determine whether a pre-discharge videotape introducing the concept and benefit of a cardiac rehabiliation \& secondary prevention (crsp) program will increase intent to participate in a crsp program in post myocardial infarction, unstable angina, coronary artery bypass surgery, or coronary angioplasty patients.

there is compelling evidence that a comprehensive cr program comprising the delivery of lifestyle modifying education will reduce mortality, morbidity and improve quality of life in patients following myocardial infarction, unstable angina, angioplasty or coronary artery bypass. however less than 20% of eligible patients participate in crsp programs. this study will look at a method of potentially improving enrollment and adherence to a crsp program. patients will be randomized into two groups. one group will complete a survey and view a videotape introducing the concept of a crsp program. the second group will be requested to complete a survey only, but will not be exposed to the videotape. it is expected that the patients who view the videotape will be more likely to express intent to participate in crsp versus those patients who do not view the videotape.

Eligibility criteria:
inclusion criteria: * admission to hospital for mi, ua, ptca or cabs exclusion criteria: * inability to provide written informed consent or complete the survey for any reason * previous crsp participation * patients who are scheduled to undergo coronary artery bypass surgery within 3 months following the index hospital discharge * patients with an inability to exercise due to musculoskeletal problems or previous stroke

Keywords: cardiac rehabilitation improving cardiac rehabilitation participation
non-pharmacological pain management after surgery

Conditions: Surgical Procedure, Unspecified

Summary: the purpose of this study is to test the impact of a bundled noharm conversation guide with clinical decision support intervention embedded within an electronic health record (ehr) on pain and function 3 months following surgery.


Eligibility criteria:
inclusion criteria: * all patients 18 years of age and older. * must be undergoing qualifying surgeries at participating sites. * patients under 18 years of age. exclusion criteria: - patients under 18 years of age.
study on novel peripheral blood diagnostic biomarkers for mci due to alzheimer's disease

Conditions: Alzheimer Disease

Summary: the prevalence of mild cognitive impairment (mci) is about 15%-17%. 10%-15% of mci progresses to alzheimer's disease (ad) every year. the annual incidence of mci in the normal elderly is about 1%. peripheral blood biomarkers is the key and difficult points in ad research. except expensive brain β amyloid plaque imaging, few breakthroughs of early diagnosis technology of mci due to ad can be made to facilitate clinical application. even tau-181 and tau-217 were reported in this year on lancet neurology and jama. we also need to study on the biomarkers upstream of pathological changes about senile plaque. the purpose of this program is to study the reliability and validity of plasma mirnas for early diagnosis of mci due to ad and other dementia such as dlb and ftld. the clinical diagnosis of ad and mci due to ad are according to the national institute of aging and the alzheimer's disease association (nia-aa) diagnostic criteria in 2011. plaque imaging is used to be golden criteria for the diagnosis of ad and mci due to ad.


Eligibility criteria:
inclusion criteria: * 2011 nia-aa criteria of mci due to ad or ad or - 2017 diagnosis and management of dementia with lewy bodies: fourth consensus report of the dlb consortium or - 2001 the mckhann consensus clinical criteria for ftd (mckhann et al.) exclusion criteria: * dementia caused by infection or substance * thyroid disease
compact - combining plasma-filtration and adsorption clinical trial

Conditions: Shock, Septic

Summary: the study objective is to clarify whether the application of cpfa (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce mortality and prevent organ failures in septic shock patients in intensive care unit (icu).

septic shock is a life-threatening clinical condition characterized by cardiovascular failure as a consequence of infection. septic shock frequently causes multi-organ failure in the icu. for this reason the extracorporeal therapies for the treatment of renal failure have become widespread in the icu and, at the same time, new extracorporeal depurative techniques have been developed for the removal of inflammatory mediators. one of these techniques is cpfa (coupled plasma-filtration adsorption) that uses a sorbent once the separation between plasma and blood has been obtained with a plasma filter. the study objective is to clarify whether the application of cpfa in addition to the current clinical practice is able to reduce mortality and prevent organ failures in septic shock patients in intensive care unit.

Eligibility criteria:
inclusion criteria: * all patients admitted to the icu in septic shock * all patients that develop septic shock while in the icu exclusion criteria: * age less than 18 years * pregnancy * cardiopulmonary resuscitation * cerebral coma * metastatic cancer * presence of relative or absolute contraindications to cpfa * estimated life expectancy less than 2 weeks * already included in the study * admission from an other icu where the patient remained for more than 24 hours * absence of informed consent

Keywords: intensive care shock, septic adsorption sorption detoxification
diagnosis of gastric precancerous lesions by a blood test gastropanel in patients with increased gastric cancer risk

Conditions: Gastric Cancer; Gastric Precancerous Lesions

Summary: despite the declining incidence, gastric cancer (gc) remains the second leading cause of cancer death worldwide. in france, it is the second digestive cancer with 7,000 new cases per year. it is now well demonstrated that patients with h. pylori infection, atrophic gastritis and intestinal metaplasia, have a high risk of developing gc. it is therefore important to detect these pre-neoplastic lesions at an early stage to improve patients prognosis. thus, the aim of this project is to investigate the possible screening of gastric precancerous lesions by a blood test (gastropanel®) in france, in patients with oesophagogastroduodenoscopy (egd) prescription.


Eligibility criteria:
inclusion criteria: * patients undergoing oesophagogastroduodenoscopy (egd) according to usual care * patients with increased risk of gastric cancer (at least one of the following criteria): * age \> 50 years, * family cases of gastric cancer, * known precancerous lesions, * biermer disease, * h. pylori infection, * genetic predisposition (ex: lynch syndrome), * malt lymphoma, * dyspepsia. * subjects affiliated with an appropriate social security system exclusion criteria: * subjects with known active cancer * pregnancy * patients receiving proton-pump inhibitors * conditions that may interfere with the study objectives according to the investigator

Keywords: gastric cancer gastric precancerous lesions blood test
effects of physical exercise on response to treatement in breast cancer

Conditions: Breast Cancer

Summary: the goal of this clinical trial is to learn how regular physical exercise affects breast cancer patients' response to standard neoadjuvant chemotherapy (nac) and to gain an insight into the molecular mechanisms underlying the effects of exercise on cancer biology. of exercise-induced alterations in cancer gene expression and the immune tumor microenvironment. the main questions it aims to answer are: * does a high-intensity interval training (hiit) program during treatment improve patients' response to nac and quality of life as compared to low level of physical activity during the treatment? * what are the differences in the residual tumor gene expression and tumor infiltrating immune cell profile between patients taking hiit during the nac and patients with low level of physical activity? * what are the roles of extracellular vesicles (evs) in mediating the effects of exercise on cancer progression? patients in hiit group will undergo a personalized hiit program consisting of 3 training sessions per week for the whole duration of nac, whereas patients from the control group (ctrl) will be advised to maintain their usual level of physical activity during nac. after the breast surgery, response to nac will be assessed by miller-payne grading. tumor and normal breast tissue specimens will be collected for rna sequencing analysis. blood samples will be collected before and immediately after the training for the analysis of rna and protein cargo of circulating evs.


Eligibility criteria:
inclusion criteria: * primary breast cancer; stage iia-b, iiia-c (tnm: t1-4, n0-3, m0) at diagnosis * diagnosis established by core needle biopsy * age 30-65 years * prescribed doxorubicin/cyclophosphamide-based nac * oral and written consent exclusion criteria: * cardiac pathologies * pregnancy * blood transfusion in the last six months * another oncological disease * previous chemotherapy, hormonal or x-ray treatment * participation in another clinical trial * currently performing more than 180 min of moderate to high intensity aerobic training per week

Keywords: high intensity interval training
the effects of elmore oil on patients with osteoarthritis

Conditions: Degenerative Arthritis; Inflammation

Summary: the treatment of osteoarthritis, a disease that eventually affects the majority of the older population, involves the alleviation of symptoms such as pain and stiffness, and the reduction of inflammation. a double-blind, placebo-controlled, crossover study will be performed to examine the effect of topical application of elmore oil, a herbal remedy (containing eucalyptus oil, tea tree oil, olive oil and vanilla), which has recently been reported to have anti-inflammatory properties, on the symptoms of osteoarthritis.

sixty patients were randomly selected and approved for the study, 30 patients with even numbers received the blue dotted elmore oil and 30 patients with odd numbers got the orange dotted elmore and were advised to apply 3x daily on the affected knees respectively for four weeks. on the fifth week, they stopped application for 7 days as flush out period. then on the 6th week a cross over was done on the patients - the blue dotted patients, this time received the orange dotted elmore oil and vice-versa and did the application three times daily for another 4 weeks. all throughout the usage, they filled out their diaries (noting the degree of pain, feeling of well being (improved sleep, mobility, ability to do their daily activities at home or at work). a pre-application base line laboratory tests were done, after 4 weeks and after 8 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed osteoarthritis based on the criteria developed by the american college of rheumatology. exclusion criteria: * using other forms of topical pain relief.

Keywords: osteoarthritis osteoarthritic pain arthritic pain arthritis joint inflammation arthralgia